Drug
Ribavirin (SCH 018908)
Ribavirin (SCH 018908) is a pharmaceutical drug with 2 clinical trials. Historical success rate of 50.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(50%)
Phase Distribution
Ph phase_4
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Terminated(1)
Detailed Status
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (100.0%)
Trials by Status
completed150%
terminated150%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_4
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
NCT00687544
completedphase_4
PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)
NCT00724620
Clinical Trials (2)
Showing 2 of 2 trials
NCT00687544Phase 4
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
NCT00724620Phase 4
PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2